Journal of Immunology Research / 2017 / Article / Tab 5 / Review Article
Regulatory T Cells and Their Prognostic Relevance in Hematologic Malignancies Table 5 Most relevant published studies investigating the frequency and the prognostic significance of Tregs in chronic myeloid leukemia.
Reference Patients/controls evaluated Samples tested Marker panel used in Treg evaluation by flow cytometry Treg frequency Functional studies Impact on prognosis Zahran and Badrawy [62 ] CML/controls PB CD4/CD25/FoxP3 Increased Not performed Correlations with the level of BCR/ABL, basophils and blast cells. Significantly higher in accelerated phase and blastic phase than in chronic phase and with high Sokal score. Reduction of Tregs after therapy with IM Hus et al. [65 ] CP CML/controls PB CD4/CD25/FoxP3 Increased Not performed Correlation with higher basophiles. No change in frequency after 6 months of TKI inhibitors Bachy et al. [74 ] CP CML/controls CD4+ enriched PBMC cells CD4/CD25/CD127/FoxP3 Increased in PB. Increased in BM of patients on IM compared to healthy volunteers. No difference in inhibition Correlation with Sokal risk score Rojas et al. [63 ] CP CML/controls PBMC CD4/CD25/CD127/CD62L/FoxP3 Lower in patients in complete cytogenetic response Enhanced proliferative response to purified protein derivative Not evaluated Nadal et al. [64 ] CP CML/controls PBMC CD4/CD25/CD127/FoxP3/CTLA-4 Higher frequencies after transplant than normal controls and newly diagnosed patients Purified Tregs from SCT patients had a more potent suppressive activity than those from healthy volunteers Not evaluated
CP: chronic phase; BM: bone marrow; IM: imatinib; PB: peripheral blood; PBMC; peripheral blood mononuclear cells; BM: bone marrow; SCT: stem cell transplant; IM: imatinib; TKI: tyrosine kinase inhibitor.